drugset / Trial / NCT05805072
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of selinexor and HAAG +/- HMA in relapsed/refractory acute leukemia (AML) patients.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aclacinomycin | Unknown | 10 mg | Intravenous |
| Subject | Azacitidine | Other / unclassified | 20 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Homoharringtonine | Small molecule | 1 mg | Intravenous |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | Granulocyte colony-stimulating factor | Protein / enzyme biologic | 50 ug/m2 | Intravenous |
| Background | Granulocyte colony-stimulating factor | Protein / enzyme biologic | 600 ug/m2 | Intravenous |